The Lancet Haematology

Published by: Elsevier Science, Inc.  

People

  1. Giralt
    Giralt
  2. Noy
    Noy
  3. Stein
    Stein
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. Abdel-Wahab
    Abdel-Wahab
  7. Boelens
    Boelens
  8. Dogan
    Dogan
  9. Goldberg
    Goldberg
  10. Hassoun
    Hassoun

Groups

  1. Department of Medicine (35)
  2. Hematologic Malignancies, Division of (32)
  3. Center for Hematologic Malignancies (31)
  4. Lymphoma (13)
  5. Bone Marrow Transplant (10)
  6. Hematology-Oncology Fellows (10)
  7. Survivorship Research (8)
  8. Adult Leukemia (7)
  9. Tow Center for Developmental Oncology (TCDO) (7)
  10. CTCR Scholars (6)
Search Within
Formats
  1. Journal Article (32)
  2. Review (10)
  3. Correspondence (4)
  4. Editorial (4)
Groups
  1. Department of Medicine (35)
  2. Hematologic Malignancies, Division of (32)
  3. Center for Hematologic Malignancies (31)
  4. Lymphoma (13)
  5. Bone Marrow Transplant (10)
  6. Hematology-Oncology Fellows (10)

More Groups

People
  1. Sergio Giralt (5)
  2. Ariela Noy (4)
  3. Eytan Stein (4)
  4. Martin Tallman (4)
  5. Anas Younes (3)
  6. Matthew Matasar (3)

More People

Years
  1. 2025 (2)
  2. 2024 (8)
  3. 2023 (4)
  4. 2022 (5)
  5. 2021 (10)
  6. 2020 (10)

More Years

Publishers
  1. Elsevier Science, Inc. (50)

Results (50)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Off-the-shelf iPSC natural killer-cell therapy: A new chapter for B-cell lymphoma?
    Editorial

    Tix, T.; Rejeski, K.
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): Results from a randomised, open-label, phase 3 trial
    Journal Article

    Mina, R.; Mylin, A. K.; Yokoyama, H.; Magen, H.; Alsdorf, W.; Minnema, M. C.; Shune, L.; Isufi, I.; Harrison, S. J.; Shah, U. A.; more...
    The Lancet Haematology (2025)

    Fulltext@MSK | Save
  • Frontline treatment of adults with newly diagnosed B-cell acute lymphoblastic leukaemia
    Review

    Aldoss, I.; Roboz, G. J.; Bassan, R.; Boissel, N.; DeAngelo, D. J.; Fleming, S.; Gökbuget, N.; Logan, A. C.; Luger, S. M.; Menne, T.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Radiotherapy for haematological malignancies
    Correspondence

    Dee, E. C.; Wu, J. F.; Feliciano, E. J. G.; Jacomina, L. E.; Yahalom, J.
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
    Journal Article

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Urgent need: Evidence-based use of donor lymphocyte infusions
    Correspondence

    Boelens, J. J.; Scordo, M.
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Immune effector cell-associated haematotoxicity after CAR T-cell therapy: From mechanism to management
    Review

    Rejeski, K.; Jain, M. D.; Shah, N. N.; Perales, M. A.; Subklewe, M.
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
    Journal Article

    Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T. S.; Arnulf, B.; Cavo, M.; Nooka, A.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: A prospective cohort study
    Journal Article

    Cargo, C.; Bernard, E.; Beinortas, T.; Bolton, K. L.; Glover, P.; Warren, H.; Payne, D.; Ali, R.; Khan, A.; Short, M.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: Updated recommendations by the EBMT/ELN International Working Group
    Review

    Kröger, N.; Bacigalupo, A.; Barbui, T.; Ditschkowski, M.; Gagelmann, N.; Griesshammer, M.; Gupta, V.; Hamad, N.; Harrison, C.; Hernandez-Boluda, J. C.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save

    • The Lancet Haematology – authorized name for:

    Name ISSN / ISBN Publisher
    Lancet Haematology 2352-3026 Unknown
    Lancet Haematology 2352-3026 Elsevier Science, Inc.
    Lancet Haematology 2352-3026 Elsevier Science, Inc.
    The Lancet Haematology 24519960 Unknown
    The Lancet Haematology 24519960 Elsevier Inc.
    The Lancet Haematology 2352-3026 Elsevier Inc.
    The Lancet Haematology 23523026 Unknown
    The Lancet Haematology 23523026 Elsevier Inc.
    The Lancet Haematology 23523026 Elsevier L D
    The Lancet Haematology 2352-3026 Elsevier Science, Inc.
    The Lancet Haematology 2352-3026 Elsevier Inc.